The French biotech company CELLIPSE has taken the next step towards novel treatments for leukaemia patients thanks to the European Lead Factory.
They have now received the so-called Qualified Hit List from the European Lead Factory for their innovative approach targeting the cytoskeleton regulation. Renaud Prudent, Chief Operating Officer of CELLIPSE, thanked the ELF teams involved: 'Despite some unexpected difficulties along the way, they managed to deliver the results that we anticipated. This will allow us to build a second chemistry asset programme, to strengthen our ongoing proprietary lead candidates portfolio of kinase inhibitors for myeloid leukemias.'
Interested? Read more on their website.
© European Lead Factory and its partners.
The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n' 115489, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7 / 2007-2013) and EFPIA companies' in kind contribution.
This project has also received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806948: ‘ESCulab: European Screening Centre; Unique Library for Attractive Biology’. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Medicines for Malaria Venture (MMV).